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Abstract
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512
HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic and 28,714 (59%) autologous, reported by 700 centers in 51
countries during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid malignancies 27,895 (64%),
and nonmalignant disorders 3173 (7%). A marked growth in CAR-T cellular therapies from 151 in 2017 to 1134 patients in
2019 is observed. This year’s analyses focus on changes over 30 years. Since the first survey in 1990 where 143 centers
reported 4234 HCT, the number has increased to 700 centers and 48,512 HCT. Transplants were reported in 20 countries in
1990, and 51, 30 years later. More than 800,000 HCT in 715,000 patients were reported overall. Next to the massive
expansion of HCT technology, most notable developments include the success of unrelated donor and haploidentical HCT,
an increase followed by decrease in the number of cord blood transplants, use of reduced intensity HCT in older patients, and
the phenomenal rise in cellular therapy. This annual report of the European Society for Blood and Marrow Transplantation
(EBMT) reflects current activity and highlights important trends vital for health care planning.
Introduction
The European Society for Blood and Marrow Transplanta-
tion (EBMT) published for the first time in 1990 [1] a
survey describing activity in hematopoietic stem cell
transplant centers in Europe. Since then, this survey was
published annually and herewith will be the 30th anniver-
sary edition. The survey includes over 700,000 patients with
over 800,000 transplants. Initially the survey was designed
in the form of a single page spreadsheet for ease of
reporting and has remained in this format ever since,
although many additional features had been added, such as
refined disease classification, information on conditioning
intensity, pediatric activity, cell source, and cellular therapy.
Hematopoietic cell transplantation (HCT) is an estab-
lished procedure for many acquired or inherited disorders of
the hematopoietic system, benign or neoplastic, including
those of the immune system, and as enzyme replacement in
metabolic disorders [2–4]. The activity survey of the
EBMT, describing the status of HCT, has become an
instrument with which to observe trends and monitor
changes in HCT technology in Europe and neighboring
countries [5–14]. The survey, using a standardized struc-
ture, captures the numbers of HCT from highly committed
participating centers, stratified by indication, donor type,
and stem cell source. In the last few years, the survey has
also included information on cellular therapies with hema-
topoietic cells for uses other than to replace the hemato-
poietic system [15–28, https://www.ema.europa.eu/en/
documents/scientific-guideline/qualification-opinion-cellula
r-therapy-module-european-society-blood-marrow-transpla
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ntation-ebmt_en.pdf]. The analysis of the survey data since
1990 shows a continued and constant increase in the annual
numbers of HCT and transplant rates for both allogeneic
and autologous HCT. This report, based on the 2019 survey
data, shows recent trends, changes in indications, and use in
Europe and collaborating countries and summarizes the last
30 years.
Patients and methods
Data collection and validation
We invited participating centers to report their data for 2019
using the activity survey as shown in Table 1. The survey
allows the reporting of additional information on the num-
bers of subsequent transplants performed due to relapse,
rejection, or those that are part of a planned sequential
protocol. Information on the numbers of patients receiving
unmanipulated donor lymphocyte infusions (DLIs), non-
myeloablative or reduced intensity HCT, and the numbers
of pediatric HCT is also collected.
In addition, centers report information on different types
of cellular therapies qualifying as advanced therapy med-
icinal products (ATMP) since they result from substantial
manipulations of the collected cells, whether manufactured
by industry centrally, or locally by an academic institution.
Quality control measures included several independent
systems: confirmation of validity of the entered data by the
reporting center, selective comparison of the survey data
with MED-A data sets in the EBMT Registry database and
crosschecking with National Registries.
Centers
Since 1990, a directory of HCT centers consisting of both
members of the EBMT and non members, in both Eur-
opean and collaborating non-European countries has been
accrued. The directory is updated annually according to the
centers current activity. In 2019, 730 centers from 53
countries were contacted (42 European and 11 collaborat-
ing countries); of which 700 centers responded. This cor-
responds to a 96% return rate and includes 82% of EBMT
members. Thirty active centers failed to report in 2019.
Reporting centers are listed in the Supplementary Online
Appendix in alphabetical order, by country, city, and
EBMT center code, with their reported numbers of first and
total HCT, and of first allogeneic and autologous HCT. The
WHO regional office definitions were used to classify
countries as European or non-European. Ten collaborating
non-European countries participated in the 2019 EBMT
survey: Algeria, Iran, Iraq, Jordan, Lebanon, Nigeria, Saudi
Arabia, South Africa, Syria, and Tunisia. Their data, 2590
HCT in 2502 patients, from 31 actively transplanting
centers make up 5.3% of the total data set and are included
in all analyses.
Patient and transplant numbers
Wherever appropriate, patient numbers corresponding to
the number of patients receiving a first transplant in 2019,
and transplant numbers reflecting the total number of
transplants performed are listed. The term sibling donor
includes HLA identical siblings and twins but not siblings
with HLA mismatches. Unrelated donor transplants include
HCT from matched or mismatched unrelated donors with
peripheral blood and bone marrow as a stem cell source but
not cord blood HCT. Haploidentical transplants are being
described as any family member with 2 or more (but not
more than 5) loci mismatches within the loci HLA-A, -B,
-C, -DRB1, and -DQB1 in GvH and/or HvG direction.
Other family member donors are those related donors that
are mismatched to a lesser degree than a full haplotype. For
the purpose of analysis we add the small number of “other
family donor” to haploidentical donor HCT. Additional
non-first transplants may include multiple transplants
defined as subsequent transplants within a planned double
or triple autologous or allogeneic transplant protocol, and
re-transplants (autologous or allogeneic) defined as
unplanned HCT for rejection or relapse after a previous
HCT.
Hematopoietic advanced cellular therapies other
than hematopoietic cell transplantation
Centers were requested to report all patients receiving cel-
lular therapies other than HCT in 2019. Hematopoietic
advanced cellular therapies were defined as infusion of cells
undergoing substantial manipulation after collection, either
selection and/or expansion, or genetic modification and thus
qualify as investigational or approved ATMPs according to
Regulation (EC) N° 1394/2007. In this context, “sub-
stantial” should be understood as referring to the definition
included in the Regulation and subsequent regulatory
documents and may not reflect the workload assumed by
cell processing facilities working in conjunction with clin-
ical programs. Depending on their nature and indications,
hematopoietic cellular therapies may be designed to replace
or to complement HCT. Administration of non-substantially
manipulated hematopoietic cells, such as transplantation of
CD34+ selected hematopoietic stem cells is counted as
HCT and not as cellular therapy [15]. Similarly, unmani-
pulated lymphocyte infusions post-HCT are counted as
DLIs and not cellular therapy. Hematopoietic cellular
therapies include immune effector cells as defined in FACT-
JACIE standards for Hematopoietic Cellular Therapy:
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Family Unrelated Allo Auto Total
HLA-id Twin Haplo ≥
2MM
Other family BM BM+
BM PBPC Cord All BM PBPC BM PBPC Cord BM PBPC Cord Only PBPC Cord
Myeloid malignancies 294 2562 9 13 367 1359 14 73 0 417 5292 118 0 245 1 10,518 246 10,764
Acute myeloid leukemia 227 1799 5 12 268 986 9 56 0 253 3305 87 0 237 0 7007 237 7244
1st Complete remission 144 1163 1 9 154 523 4 37 0 153 1852 38 0 193 0 4078 193 4271
Not 1st complete remission 58 427 4 3 74 327 4 16 0 72 848 35 0 41 0 1868 41 1909
AML therapy-related or myelodysplasia-related changes 25 209 0 0 40 136 1 3 0 28 605 14 0 3 0 1061 3 1064
Chronic myeloid leukemia 7 103 1 1 6 46 0 0 0 20 209 2 0 0 0 395 0 395
Chronic phase 3 54 1 0 2 13 0 0 0 7 91 2 0 0 0 173 0 173
Not chronic phase 4 49 0 1 4 33 0 0 0 13 118 0 0 0 0 222 0 222
MDS or MD/MPN overlap 52 475 3 0 64 259 4 14 0 130 1283 26 0 7 1 2310 8 2318
MPN 8 185 0 0 29 68 1 3 0 14 495 3 0 1 0 806 1 807
Lymphoid malignancies 312 1321 8 6 207 841 9 51 1 346 2093 60 30 22,610 0 5255 22,640 27,895
Acute lymphatic leukemia 267 745 6 0 124 478 7 34 1 286 1044 52 0 66 0 3044 66 3110
1st Complete remission 149 535 3 0 54 243 5 23 0 144 686 24 0 62 0 1866 62 1928
Not 1st complete remission 118 210 3 0 70 235 2 11 1 142 358 28 0 4 0 1178 4 1182
Chronic lymphocytic leukemia 4 40 0 0 6 19 0 0 0 3 99 0 0 11 0 171 11 182
Plasma cell disorders—MM 2 89 0 3 5 24 0 1 0 5 140 0 7 13,245 0 269 13,252 13,521
Plasma cell disorders—other 0 5 0 0 5 3 0 0 0 0 14 0 0 442 0 27 442 469
Hodgkin lymphoma 11 113 0 1 32 112 1 3 0 12 147 2 10 2175 0 434 2185 2619
Non Hodgkin lymphoma 28 329 2 2 35 205 1 13 0 40 649 6 13 6671 0 1310 6684 7994
Solid tumors 3 2 0 0 3 14 0 0 0 2 4 1 18 1529 0 29 1547 1576
Neuroblastoma 2 2 0 0 3 9 0 0 0 0 1 0 10 489 0 17 499 516
Soft tissue sarcoma/Ewing 1 0 0 0 0 2 0 0 0 0 1 1 2 245 0 5 247 252
Germinal tumors 0 0 0 0 0 0 0 0 0 0 1 0 2 431 0 1 433 434
Other solid tumors 0 0 0 0 0 3 0 0 0 2 1 0 4 364 0 6 368 374
Nonmalignant disorders 731 343 25 7 123 205 65 55 1 530 461 58 7 561 1 2604 569 3173
Bone marrow failure—SAA 185 140 0 5 21 54 5 10 0 181 138 10 0 1 1 749 2 751
Bone marrow failure—other 56 28 2 1 20 18 8 9 0 75 52 4 0 0 0 273 0 273
Thalassemia 154 45 9 0 2 11 17 9 1 42 52 0 1 0 0 342 1 343
Sickle cell disease 163 87 8 0 26 9 12 1 0 11 7 0 0 0 0 324 0 324
Primary Immune deficiencies 136 28 6 0 44 103 21 19 0 174 169 19 4 8 0 719 12 731
Inh. disorders of Metabolism 32 12 0 1 10 9 2 5 0 46 33 25 2 13 0 175 15 190
Autoimmune disease—MS 0 0 0 0 0 0 0 0 0 0 1 0 0 442 0 1 442 443
Autoimmune disease—SSC 0 0 0 0 0 0 0 0 0 0 0 0 0 55 0 0 55 55






































“A cell that has differentiated into a form capable of mod-
ulating or effecting a specific immune response” [25, 26].
This definition covers CAR-T cells and forms the basis for
accreditation requirements in recent EBMT-JACIE recom-
mendations [16].
Hematopoietic cellular therapies were categorized as
chimeric antigen receptor T-cells (CAR -T); in vitro selec-
ted/and or expanded T-cells or cytokine activated, such as
virus specific T-cells; cytokine-induced killer cells (CIK);
regulatory T cells (TREGS); genetically modified T cells
other than CAR-T; natural killer cells; dendritic cells;
mesenchymal stromal cells; in vitro expanded CD34+ cells;
and genetically modified CD34+ cells. This survey does
not include cells from sources other than hematopoietic
tissue [19]. On the other hand, gene therapy protocols, such
as those used to treat thalassemia or SCID are part of this
survey, but currently numbers are low.
Transplant and cellular therapy rates
Transplant rate, defined as the total number of HCT per
10 million inhabitants were computed for each country
(based on the center report), without adjusting for patients
receiving their HCT in a foreign country. Cellular therapy
rates are defined as the numbers of patients receiving a
cellular therapy treatment per 10 million population. Center
density is defined as the number of centers performing
a certain type of procedure per 10 million population.
Population numbers for the European countries in 2019
were obtained from Eurostats: (http://appsso.eurostat.ec.
europa.eu) and the World Bank database for the non-
European countries: (https://databank.worldbank.org).
Analysis
Wherever appropriate, the absolute numbers of transplanted
patients, transplants or transplant rates are shown for spe-
cific countries, indications, or transplant techniques. Mye-
loid malignancy includes acute myeloid leukemia (AML),
myelodysplastic or myelodysplastic/myeloproliferative
neoplasia (MDS or MDS/MPN overlap), myeloproliferative
neoplasm (MPN), and chronic myeloid leukemia (CML).
Lymphoid malignancy includes acute lymphocytic leuke-
mia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin
lymphoma (HL), non-Hodgkin lymphoma (NHL), and
plasma cell disorders (PCD) (which includes multiple
myeloma (MM) and others). The nonmalignant disorders
include bone marrow failure (BMF (which includes severe
aplastic anemia (SAA) and others), thalassemia and sickle
cell disease (HG), primary immune disease (PID), inherited
diseases of metabolism (IDM), and autoimmune diseases
(AID). Others include histiocytosis and other rare disorders
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Results
Participating centers in 2019
Of the 700 centers, 451 (64%) performed both allogeneic
and autologous transplants; 229 (33%) restricted their
activity to autologous HCT, and 18 (3%) to allogeneic
transplants only. Two of the 700 responding centers
reported no activity due to renovation or changes within
the transplant unit. Within the 698 actively transplanting
centers in 2019, 128 (18%) performed transplants on both
adult and pediatric patients. An additional 122 (18%)
were dedicated pediatric transplant centers and 448 (64%)
perform transplants on adults only. Thirty centers failed
to report in 2019, which, when compared with
previously reported data, accounts for ~780 non-
reported HCTs.
Numbers of patients, transplants, and trends in
2019
In 2019, 48,512 transplants were reported in 43,581 patients
(first transplant); of these, 19,798 HCT (41%) were allo-
geneic and 28,714 (59%) autologous (Table 1). Compared
with 2018, the total number of transplants increased by
2.2% (0.9% allogeneic HCT and 3.1% autologous HCT)
[13]. The corresponding number of patients showed an
increase of 0.4% for allogeneic HCT and 2.5% for auto-
logous HCT. In addition, there were 4931 s or subsequent
transplants, 1235 being allogeneic, mainly to treat relapse or
graft failure and 3696 autologous, the majority of which
were likely to have been part of multiple transplant proce-
dures such as tandem procedures, or as salvage
autologous transplants for PCD. Furthermore, 819 of the
allogeneic HCTs were reported as being given after a pre-
vious autologous HCT and were mainly for lymphoma
or PCD.
The number of pediatric patients (<18 years old at
transplant) transplanted in both dedicated pediatric and joint
adult-pediatric units was 5189 (3990 allogeneic and 1199
autologous). This is an overall decrease of 3.3% in the total
number of transplants; 2.1% allogeneic and 7.3% auto-
logous HCT when compared to 2018. Of these, 3987
patients, (3123 allogeneic (78%), and 864 autologous
(22%)) were treated in 121 dedicated pediatric centers in
27 countries. Due to the design of the survey, detailed
analysis is limited in the dedicated centers only. Main
indications for allogeneic HCT were AML (n= 414; 70%
in early stage), ALL (n= 766; 45% in early stage), and
NMD (n= 1534; 39% PID). There were 1625 family and
1498 unrelated donor HCTs reported. Within family donors,
42% were from a haploidentical relative. Bone marrow was
used as the stem cell source in 1628 patients of which 56%
were family donors. Peripheral blood stem cells were used
in 1376 patients with equal proportions seen in both family
(n= 685) and unrelated donors (n= 691). Cord blood stem
cells were used in 119 patients of which 75% were unre-
lated HCT. The main indications for autologous HCT, were
solid tumors, with 647 HCT reported in 2019, primarily for
neuroblastoma (49%).
Main indications
Indications for HCT in 2019 are listed in detail in Table 1
(Fig. 1a, b show distribution of disease indications for
allogeneic (Fig. 1a) and autologous (Fig. 1b) HCT). Main
indications for allogeneic HCT were myeloid
malignancies (AML, CML, MDS or MDS/MPN overlap
and MPN): 10,518 (98% allogeneic HCT and 2% auto-
logous HCT). For autologous HCT, the main
indications were lymphoid malignancies (ALL, CLL, PCD,
HL, and NHL): 22,640 (19% allogeneic HCT and 81%
autologous HCT).
Allogeneic HCT
The leading indication for allogeneic HCT was AML,
which accounts for 38% of all allogeneic HCT, an increase
of 1% when compared to 2018. Increases were seen in both
early disease stage (1.7%) and therapy-related AML or
those with myelodysplasia-related changes (3.5%). AML in
late disease stage decreased by 2.2%. Among the myeloid
malignancies, CML continues to increase overall by 6.2%.
However, differences were seen in 1st chronic phase with a
decrease of 14.4% and advanced phase which increased by
30.6%, although overall the numbers remain low (n= 395
patients). Allogeneic HCT for MDS decreased slightly by
0.5% to 2310 patients treated. MPN increased by 7.8% from
748 in 2018, to 806. ALL comprises 16.4% of allogeneic
HCT and showed a slight increase overall of 2.7% com-
pared to the previous year. Again, differences were seen
between early stage, increasing by 4.8% and late stage,
decreasing by 0.6%. Allogeneic HCT for CLL continued to
decrease by 10.9% when compared to 2018, a constant
trend over recent years. Allogeneic HCT for NHL decreased
by 4.1% to 1310 while for HL, rates remained stable.
Within the nonmalignant disorders, a continued increase of
3.7% is seen for BMF—SAA (n= 749), and of 17.7% for
BMF—non SAA (n= 273). PID increased by 6.4% (n=
719) and sickle cell disease by 44% (n= 324). For IDM, the
rate decreased by 11.6% (n= 175) and for thalassemia by
17.4% (n= 342). Allogeneic HCT for AID remain a rare
indication with just 22 patients treated in 2019, although
there is an overlap with PID and other inherited disorders
that would benefit from better definition for future reporting
[27]. Within allogeneic HCT, 7625 were performed using
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non-myeloablative or reduced intensity conditioning in
2019. This comprises 39% of all allogeneic HCTs, a rate
that has remained stable over the last 10 years.
Autologous HCT
The main indications for autologous HCT were lymphoid
malignancies (90%) with PCD comprising 55% of all
autologous HCT patients. Autologous HCT for NHL has
not changed over time up to 2019 while PCD have
increased slightly by 4.2%. As reported in 2018, AML
continued to decrease by 19.1% and ALL by 10.8%. For
solid tumors and AID, the numbers remained stable. In
2019, the activity survey was adapted to capture more
defined data for AID. The majority were performed for
multiple sclerosis (n= 442), followed by systemic sclerosis
(n= 55) and other AID (n= 42).
Transplant rates and center density
Assessing transplant rates per 10 million population (TR)
allows the comparison of activity in countries where popu-
lation numbers differ greatly. Center density per 10 million
population allows the comparison of activity by the number
of centers. The TR rates for allogeneic HCT, ranged from
0.2 in Nigeria to 476.1 in Israel (median number of HCT
127 and TR 144) (Supplementary Fig. 1a). Five countries
did not report any allogeneic HCT (Armenia, Bosnia and
Herzegovina, Cyprus, Iceland, and Luxembourg). For
autologous HCT, rates ranged from 2.3 in Syria to 625 in
Switzerland (median number of HCT 181 and TR 281),
(Supplementary Fig. 1b). Figure 2a shows the use of CAR-T
cells in 2019 on a map as treatment rates and (Fig. 2b) as
center density. Figure 2c, d correspondingly depict non-
CAR-T cellular therapies as treatment rates and as center
density respectively.
Donor type and stem cell source
In 2019, the overall numbers of patients treated with
family donors remained stable, however, variation was
seen within the choice of family donor used. HLA iden-
tical sibling and syngeneic twin donors decreased by 6%
when compared to 2018 but increases were observed in
haploidentical donors of 11% and unrelated donors of
1.2%. The cord blood HCT rate continued to decrease
slowly (1%) and mainly included unrelated cord blood
(85%). In sibling donors, peripheral blood and bone
marrow stem cell use decreased by 6.2% and 5.6%
respectively. In haploidentical donors, an increase of
17.8% was seen in the use of stem cells harvested from
peripheral blood while use of bone marrow stem cells
decreased by 6.8%. In unrelated donor transplants, the use
of bone marrow and cord blood stem cells has decreased
by 4.5% and 4%, respectively. For allogeneic HCT, the
numbers increased only slightly (0.4%) and the proportion
of those using bone marrow decreased by 5.4%. When
compared to 2018, the absolute numbers of patients
treated with autologous HCT has continued to increase
(2.5%) and since 1996 are predominantly performed using
peripheral blood stem cells (>90%).
Thirty-year overview
The first activity survey was conducted in 1990 and presented































Fig. 1 Relative proportion of disease indications for HCT in
Europe 2019. a Relative proportion of allogeneic HCT. b Relative
proportion of autologous HCT.
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Fig. 2 Cellular therapy rates per 10 million population in Europe 2019. a Patients treated with CAR-T cellular therapy. b Number of centers
performing CAR-T cellular therapies. c Patients treated with non CAR-T cellular therapy. d Number of centers performing non CAR-T cellular
therapies.
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Since this first survey, revisions were made to ensure that each
annual survey was optimized for the current changes in
technology and treatment protocols used at the time. The
survey allows us to monitor activities and trends over a
30-year period. The number of reporting centers has increased
from 143 to 700 in 2019, and from 20 countries to 51.
Allogeneic HCT has increased from 2137 to 19,798, while
autologous HCT has increased from 2097 to 28,714.
Figure 3a shows the development in the numbers of
patients treated with autologous and allogeneic HCT over
the 30-year period. Figure 3b shows the distribution of
donor type among allogeneic HCT recipients depicting the
importance of unrelated donor and haploidentical donor
HCT globally in the recent decade. Figure 4 shows the
changes in choice of stem cell source for allogeneic HCT.
Autologous HCT does not warrant graphical depiction as
the use of bone marrow has almost disappeared. It is evident
that for allogeneic HCT, growth is due to the use of per-
ipheral blood stem cells; use of marrow remains stable at
around 3500 transplants annually and is prevalent in allo-
geneic HCTs for nonmalignant disorders (Table 1). Figure 5
addresses the number of centers performing HCT in Europe,
increasing from 143 to 700 over 30 years. The Figure shows
the number of centers performing autologous and allogeneic
HCT using sibling, unrelated and haploidentical donors as
well as cord blood. The number of centers performing
autologous HCT rose sharply in the late 90s, most likely

















































Fig. 3 Development of HCT
from 1990 to 2019. a Number
of patients receiving autologous
and allogeneic HCT.
b Distribution of donor type
among allogeneic HCT
recipients.
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Regarding allogeneic HCT, at all points in time the number
of centers performing transplants with donors other than
HLA identical siblings was lower than the number of cen-
ters performing sibling transplants. Since around 2015,
there appears to be a convergence of centers performing
allogeneic HCT using all types of available donor. Since
2012, the number of centers using cord blood donors as the
stem cell source has declined.
Cellular therapy
Table 2 shows the number of patients receiving advanced
cellular therapy and DLI performed in 2019. There were
3028 patients receiving unmanipulated DLIs, which is a
slight decrease of 2.2% since 2018. The majority of DLIs
were given for relapse (n= 1461) and graft enhancement/
failure (n= 716).
A total of 2214 patients in 198 centers from 31 countries
received other forms of hematopoietic cellular therapies that
qualify as medicinal products rather than cell transplants [15].
In 2019 the most remarkable increase was in gene-modified
T cells, notably CAR-T cells increasing from 151 in 2017 to
1134 in 2019 (650% increase). One hundred and fifteen
centers in 2019 in 19 countries reported CAR-T cellular
therapies (Fig. 2a shows rates of CAR-T-cell treatment and
Fig. 2b, center density performing CAR-T treatment). The
main indication being lymphoma (n= 826; 100% auto-
logous), followed by ALL (n= 252; 92% autologous), and
other malignancies (n= 56; 98% autologous). Much has been
written about CAR-T cellular therapy replacing autologous or
allogeneic HCT for lymphoma, Fig. 6 shows numbers of
autologous (Fig. 6a) and allogeneic (Fig. 6b) HCT for Non-
Hodgkin lymphoma and Hodgkin lymphoma over























Fig. 4 Change in choice of
stem cell source for allogeneic
HCT from 1990 to 2019.
Figure shows the change in the
use of bone marrow (BM),
peripheral blood (PB) and cord
blood (CB) as stem cell source

















Auto Sibling donor Haploidentical
Unrelated Cord blood
Fig. 5 Change in choice of
donor type by center from
1990 to 2019. The figure shows
the numbers of centers and the
type of donors selected for HCT
over the 30 year period.
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there has been an impact of CAR-T cell use on HCT. If the
more than 800 CAR-T treatments for lymphoma had replaced
HCT use, a notable decrease in activity would have been
expected. The second most widely used cellular therapy other
than CAR-T cells in 2019 is mesenchymal stromal cells (n=
359; 97% allogeneic), their use being mainly to treat graft-
versus-host disease [19]. Since 2018, an increase was also
seen in the numbers of selected/expanded T cells or CIK
(127%) and TREGS (59%). Figure 2c shows rates of non-
CAR-T-cell treatment and Fig. 2d, center density performing
non-CAR-T treatment.
Discussion
The EBMT activity survey has been conducted annually
since 1990 [1]. Over 48,000 transplants in more than 43,500
patients were reported in 2019. Starting in 2015, we
observed a slower growth for unrelated donor HCT as
compared to haploidentical HCT [12]. In the last year,
however, use of both types of donor continues to increase;
by 10% for haploidentical donors, and 1.9% for unrelated
donors. It is mostly in well-established indications where
growth is observed, such as allogeneic HCT for AML in
CR1, but also ALL in CR1, MPN, and PID.
In the 2017 report we described lower rates of aplastic
anemia transplantation possibly due to the use of throm-
bopoietin analogues such as eltrombopag. In the last 2 years
though, we see the number has increased by 28.6%, pos-
sibly suggesting that transplants are now performed later
after failing thrombopoietin analogues but also centers
proceeding quicker to transplantation as well as the growing
upfront approach for children and younger adults.
The most impressive growth is observed in hemato-
poietic cellular therapies, most notably in the use of CAR-T
cells, increasing to 1134 reported patients treated in 2019.
Since the only two approved products received a centralized
marketing approval from EMA in August 2018, it is pos-
sible that the reported activity in 2019 may still partially
reflect patients in clinical studies, either industry-sponsored
or academia sponsored [https://www.ema.europa.eu/en/
documents/scientific-guideline/qualification-opinion-cellula
r-therapy-module-european-society-blood-marrow-transpla
ntation-ebmt_en.pdf]. Investigational CAR-T cells can be
produced by academic facilities. Since the EMA approved
the first CAR-T cell product, a notable increase in the use of
CAR-T cells has been observed and a further increase is to
be expected in 2020 [22, 23]. Emergence of a rapidly
growing clinical activity is reassuring in view of earlier
reports demonstrating that Europe lagged behind the USA
and China [24]. Figure 2b illustrates wide variability in
center density for CAR-T cell treatment. Obviously, it is
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population at this point in time. The survey will continue to
observe this development. The constant and steady increase
in autologous or allogeneic HCT for NHL has not changed
over time. These are indications for autologous as well as
for allogeneic HCT which may in the future be replaced by
CAR-T treatments. So far, there is little evidence for a
replacement of transplant technology by cellular therapy
products. While the use of transplant technology for auto-
logous HCT for PCD continues to increase, the use of
allogeneic HCT for PCD is decreasing; this may be due to
the availability of more potent drugs such as monoclonal
antibodies. The 30-year comparison shows the impressive
expansion of the use of HCT technology across Europe.
Whereas one can still criticize a lack of standardization in
transplant indications and technologies, continued growth in
established indications hints at a convergence of practices
across Europe. Of interest is the use of HCT using alter-
native donors in Europe where centers specializing in cer-
tain types of transplants have given way to centers more
commonly using the entire spectrum of sibling, unrelated
donor and haploidentical donor transplantation reflecting an
increased choice of donor available for patients in need of
allogeneic HCT.
The annual activity survey of the EBMT reflects
current activity and trends in the field of transplant tech-
nology. It is valuable for the dissemination of the most
recent information on indications, donor and stem cell
usage, and benchmarking of data completeness and survival
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Fig. 6 Change in HCT for
lymphomas 1990–2019.
a Autologous HCT for Hodgkin
and non-Hodgkin lymphoma.
b Allogeneic HCT for Hodgkin
and non-Hodgkin lymphoma.
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